On October 31, 2024, Conduit Pharmaceuticals, led by CEO David Tapolczay, requested the U.S. Securities and Exchange Commission (SEC) to expedite the effectiveness of its Registration Statement on Form S-3. The company aims for the statement to become effective on November 1, 2024, at 4:30 p.m. Eastern Time.This request is made under Rule 461 of the Securities Act of 1933. The company has appointed Todd Mason of Thompson Hine LLP as the contact for any inquiries related to this request. The effectiveness of the Registration Statement is crucial for Conduit Pharmaceuticals' strategic financial planning and potential capital raising activities.

On October 31, 2024, Conduit Pharmaceuticals, led by CEO David Tapolczay, requested the U.S. Securities and Exchange Commission (SEC) to expedite the effectiveness of its Registration Statement on Form S-3. The company aims for the statement to become effective on November 1, 2024, at 4:30 p.m. Eastern Time.This request is made under Rule 461 of the Securities Act of 1933. The company has appointed Todd Mason of Thompson Hine LLP as the contact for any inquiries related to this request. The effectiveness of the Registration Statement is crucial for Conduit Pharmaceuticals' strategic financial planning and potential capital raising activities.